Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA1/2 polymorphism

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Platelets

• Publication date

  2006-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/09537100500441101PMID 16702043
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aspirin Resistance: An Evaluation of Current Evidence and Measurement Methods

  2005cited by this paper
• Glycoprotein IIIA Gene (PIA) Polymorphism and Aspirin Resistance: Is There Any Correlation?

  2005cited by this paper
• Aspirin resistance and a single gene.

  2005cited by this paper
• The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis.

  2005cited by this paper
• Selective COX-2 Inhibitors and Risk of Myocardial Infarction

  2005cited by this paper
• Narrative Review: Aspirin Resistance and Its Clinical Implications

  2005cited by this paper
• In vitro aspirin resistance detected by PFA‐100TM closure time: pivotal role of plasma von Willebrand factor

  2004cited by this paper
• Aspirin resistance in cardiovascular disease: a review.

  2004cited by this paper
• Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs.

  2004cited by this paper
• Effect of ibuprofen on cardioprotective effect of aspirin.

  2003cited by this paper
• Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease.

  2003cited by this paper
• A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

  2003cited by this paper
• Genetic variation in cyclooxygenase 1: Effects on response to aspirin

  2003cited by this paper
• Effect of ibuprofen on cardioprotective effect of aspirin.

  2003cited by this paper
• Aspirin resistance: a new independent predictor of vascular events?

  2003cited by this paper
• Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs

  2003cited by this paper
• Flow cytometry analysis of platelet cyclooxygenase‐2 expression: induction of platelet cyclooxygenase‐2 in patients undergoing coronary artery bypass grafting

  2002cited by this paper
• Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events

  2002influential reference
• Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

  2002influential reference
• Aspirin Resistance and Genetic Polymorphisms

  2002cited by this paper
• Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?

  2002cited by this paper
• Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease.

  2002cited by this paper
• Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets.

  2002cited by this paper
• Effects of Different Thrombolytic Treatment Regimen with Abciximab and Tirofiban on Platelet Aggregation and Platelet-Leukocyte Interactions: A Subgroup Analysis from the GUSTO V and FASTER Trials

  2002cited by this paper
• PlA2 Polymorphism of &bgr;3 Integrins Is Associated With Enhanced Thrombin Generation and Impaired Antithrombotic Action of Aspirin at the Site of Microvascular Injury

  2001cited by this paper
• Common variations in platelet glycoproteins: pharmacogenomic implications.

  2001cited by this paper
• Profile and prevalence of aspirin resistance in patients with cardiovascular disease.

  2001influential reference
• Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells.

  2001cited by this paper
• Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

  2001cited by this paper
• Monitoring of Aspirin (ASA) Pharmacodynamics with the Platelet Function Analyzer PFA-100®

  2000cited by this paper
• Oxidant Stress and Aspirin-Insensitive Thromboxane Biosynthesis in Severe Unstable Angina

  2000cited by this paper
• Platelet PlA2 Polymorphism and Thromboembolic Events: From Inherited Risk to Pharmacogenetics

  1999cited by this paper
• Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance.

  1999cited by this paper
• Oxidative Stress and Atherosclerosis: Its Relationship to Growth Factors, Thrombus Formation and Therapeutic Approaches

  1999cited by this paper
• A Bispecific Antifibrin-antiplatelet Urokinase Conjugate (BAAUC) Induces Enhanced Clot Lysis and Inhibits Platelet Aggregation

  1999cited by this paper
• Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans.

  1998cited by this paper
• Cyclooxygenases 1 and 2.

  1998cited by this paper
• Low concentrations of lipid hydroperoxides prime human platelet aggregation specifically via cyclo-oxygenase activation.

  1997cited by this paper
• Isoprostanes: potential markers of oxidant stress in atherothrombotic disease.

  1997cited by this paper
• Platelet glycoprotein Illa polymorphism ane coronary thrombosis

  1997cited by this paper
• Platelet glycoprotein IIIa polymorphism and coronary thrombosis.

  1997cited by this paper
• Development of Aspirin Resistance in Persons With Previous Ischemic Stroke

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

  1994cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper

• Association of platelet ADP receptor variant rs1371097 with inadequate platelet response to aspirin in Indian patients.

  2025cites this paper
• The Impact of Single Nucleotide Polymorphisms and Other Mechanisms on Aspirin Resistance.

  2025cites this paper
• The associations of candidate gene polymorphisms with aspirin resistance in patients with ischemic disease: a meta-analysis

  2024cites this paper
• The Role of Oxidative Stress and MicroRNAs in Platelet Activation and the Efficacy of Antiplatelet Therapy in Acute Myocardial Infarction

  2024cites this paper
• Transcriptome-Guided Identification of Drugs for Repurposing to Treat Age-Related Hearing Loss

  2022cites this paper
• Study of Association between RAGE Gene Polymorphism rs2070600 (G82S) and Aspirin Resistance in Coronary Artery Disease Iraqi Patients with and without Type 2 Diabetes

  2022cites this paper
• [Résistance à l'aspirine : l'ennemi de mon ami est mon ennemi].

  2021cites this paper
• Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia

  2020cites this paper
• Prevalence rate of laboratory defined aspirin resistance in cardiovascular disease patients: A systematic review and meta-analysis

  2020cites this paper
• Association of aspirin resistance with 4‐hydroxynonenal and its impact on recurrent cerebral infarction in patients with acute cerebral infarction

  2020cites this paper
• Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis

  2019cites this paper
• Role of Platelet Activation and Oxidative Stress in the Evolution of Myocardial Infarction

  2019cites this paper
• Aspirin resistance mediated by oxidative stress‐induced 8‐Isoprostaglandin F2

  2019cites this paper
• rs5911 and rs3842788 Genetic Polymorphism, Blood Stasis Syndrome, and Plasma TXB2 and hs-CRP Levels Are Associated with Aspirin Resistance in Chinese Chronic Stable Angina Patients

  2017cites this paper
• The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban)

  2017cites this paper
• Pharmacogenomics of platelet inhibitors

  2016cites this paper
• Pharmacogenomics of Oral Antithrombotic Drugs.

  2016cites this paper
• Prevalence of Aspirin Resistance in Patients with Ischemic Stroke at a Tertiary Care Center in North India

  2015cites this paper
• Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus.

  2015cites this paper
• Endothelial dysfunction in young healthy men is associated with aspirin resistance.

  2015cites this paper
• Oxidative stress in chronic vascular disease: From prediction to prevention.

  2015cites this paper
• The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta‐analysis

  2014cites this paper
• The Association of Four Common Polymorphisms from Four Candidate Genes (COX-1, COX-2, ITGA2B, ITGA2) with Aspirin Insensitivity: A Meta-Analysis

  2013cites this paper
• Genetic variation of platelet function and pharmacology: An update of current knowledge

  2013cites this paper
• The contribution of platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2G-765C) polymorphisms to platelet response in patients treated with aspirin.

  2013cites this paper
• Prognosis after cerebral ischaemia of arterial origin: clinical characteristics and genetic information

  2013cites this paper
• ASPIRIN RESISTANCE AND OxIDATIVE STRESS IN PATIENTS wITH CORONARY ARTERY DISEASE

  2013cites this paper
• Pharmacogenetics of the antiplatelet effect of aspirin.

  2012cites this paper
• Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.

  2011cites this paper
• Genetic determinants of response to aspirin: appraisal of 4 candidate genes.

  2011cites this paper
• Aspirin resistance in patients with chronic renal failure.

  2011cites this paper
• Redox‐generated isoprostanes are associated with residual platelet activity in aspirin‐treated patients with stable coronary heart disease

  2010cites this paper
• Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin.

  2010cites this paper
• Étude de l’effet des médicaments antiplaquettaires sur la fonction plaquettaire : de la variabilité de réponse à l’effet rebond

  2010cites this paper
• Variabilité de réponse plaquettaire à l’aspirine et nouvelles cibles thérapeutiques

  2009cites this paper
• ariabilité de réponse plaquettaire à l’aspirine et ouvelles cibles thérapeutiques ariable platelet response to aspirin and new herapeutic targets

  2009cites this paper
• [Variable platelet response to aspirin and new therapeutic targets].

  2009cites this paper
• The genetics of antiplatelet drug resistance

  2009cites this paper
• Aspirin Resistance is More Common in Lacunar Strokes than Embolic Strokes and is Related to Stroke Severity

  2008cites this paper
• Prognostic Modelling in Ischaemic Stroke Study, Additional Value of Genetic Characteristics

  2008cites this paper
• Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms.

  2008cites this paper
• Pharmacogenetics of aspirin resistance: a comprehensive systematic review.

  2008cites this paper
• The pharmacogenetics of antiplatelet drugs.

  2007cites this paper
• A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.

  2007cites this paper
• Coronary stent thrombosis related to aspirin resistance: what are the underlying mechanisms?

  2006cites this paper
• Personalized medicine for anticoagulation therapy

  2006cites this paper